Browse Technologies
Browse Technologies
Technology Keyword Search
Drug Discovery/Research Tools
Search Results
Displaying: 1 - 10 of 103 Results
Isolating live cells after high-throughput, long-term, time-lapse microscopy
Researchers led by Johan Paulsson have engineered a high-throughput microfluidic device for multigenerational culturing, imaging, and tracking of single-cell lineages. The platform is highly customizable and is compatible with many cell types,…
DBD
- Irit Ben-Chelouche
Investigators
- Johan Paulsson
Machine learning to accelerate diagnostics and therapeutics for COVID-19
The COVID-19 pandemic demands a rapid response of science, diagnostics, and therapeutics. Debora Marks’ lab at Harvard Medical School aims to accelerate those efforts using predictive models of the SARS-CoV2-19 sequences and 3D structures. The lab’s…
DBD
- Irit Ben-Chelouche
Investigators
- Debora Marks
Exo-site Enzyme Inhibitor Discovery Platform for Oncology Therapeutics
A startup emerging from David Liu's lab intends to commercialize a small-molecule enzyme inhibitor discovery platform to generate more potent drugs with higher specificity. (Image credit: Rose Lincoln/Harvard Staff Photographer.)Off-target drug…
DBD
- Irit Ben-Chelouche
Investigators
- David Liu
Evolution of Sequence-Defined Highly Functionalized Nucleic Acid Polymers
DESCRIPTION Template-directed synthesis of modified DNA sequences can provide a rich source of material for generating new therapies featuring modified nucleic acid polymers. The Liu lab has previously developed pioneering methods to generate…
DBD
- Irit Ben-Chelouche
Investigators
- David Liu
Novel platform for rapid, immunization-free nanobody discovery
This is a novel platform technology that can be used to expedite the development of nanobodies for therapeutic and diagnostic applications by avoiding the need for animal immunization.Nanobodies are single-domain antibodies derived from camelids…
DBD
- Grant Zimmermann
Investigators
- Andrew Kruse
SIM-PAL: proteome wide identification of small molecule binding sites
Precise target identification for small molecules is an important and essential step in drug development. Despite its importance, there are very few unbiased, proteome-wide approaches aimed at identifying binding partners for small molecules. In…
DBD
- Grant Zimmermann
Investigators
- Christina Woo
aP2 knock-out mice
AP2 knock-out mutant mice were developed by Dr. Gokhan Hotamisligil at Harvard Medical School (Science. 1996 Nov 22;274(5291):1377-9). AP2, also known as Fatty Acid-Binding Protein 4 (FABP4), encodes the adipocyte FABP. It plays important roles in…
DBD
- Vivian Berlin
Investigators
- Gokhan Hotamisligil
Polycystic Kidney Disease: Mechanistic Dissection and Discovering Precision Therapeutic Targets
Autosomal-dominant polycystic kidney disease (ADPKD) is a life-threatening monogenic disease that affects nearly 1 million people in the U.S. alone. ADPKD represents a very large unmet medical need, currently without remedy. It is characterized by…
DBD
- Grant Zimmermann
Investigators
- Adrian Salic
KRT14-Cre mouse line
Hemizygous Tg(KRT14-cre)1Amc/J (also known as K14-Cre) transgenic mice were developed in the laboratory of Dr. Andrew P. McMahon at Harvard University. The mouse strain harbors Cre recombinase under the control of human keratin-14 promoter, which…
DBD
- Vivian Berlin
Investigators
- Andrew McMahon
Ngn3-Cre transgenic mice for studying pancreatic development
Hemizygous transgenic Tg(Neurog3-cre/Esr1*)1Dam/J mice (also known as Ngn3/CreERTM) were developed in the laboratory of Dr. Douglas A. Melton at Harvard University. The mice contain a fusion protein of Cre recombinase and mutant mouse estrogen…
DBD
- Vivian Berlin
Investigators
- Douglas Melton